Reclast (Zoledronic Acid): How to Safely Stop

How Reclast Works: The Biology Behind Its Long Duration

Reclast works by binding to hydroxyapatite in bone mineral and inhibiting an enzyme called farnesyl pyrophosphate synthase inside osteoclasts, the cells that break bone down. This kills or disables osteoclasts, which tips the bone-remodeling cycle toward net bone gain. The effect is not short-lived.

Why One Yearly Infusion Is Enough

Unlike oral bisphosphonates taken daily or weekly, zoledronic acid is delivered as a single 5 mg IV infusion once yearly and concentrates in bone almost immediately after infusion. Because it binds hydroxyapatite with extremely high affinity, it is released only as bone is resorbed, re-exposing the drug gradually over years. Pharmacokinetic modeling from the HORIZON-PFT trial data shows that a clinically meaningful fraction of the administered dose remains pharmacologically active in the skeleton for at least three to five years after the last dose.

The HORIZON-PFT Trial: What It Proved

The key evidence comes from the HORIZON Key Fracture Trial, published in the New England Journal of Medicine in 2007. In 7,736 postmenopausal women with osteoporosis, three annual 5 mg infusions of zoledronic acid reduced vertebral fracture risk by 70%, hip fractures by 41%, and non-vertebral fractures by 25% compared with placebo. Every participant in that trial was a woman. The benefit was consistent across age groups from 65 to over 80.

What Happens to Bone During and After Treatment

During treatment, bone turnover markers such as serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide) fall sharply within weeks of each infusion and remain suppressed. Bone mineral density (BMD) rises at the lumbar spine by roughly 6.7% over three years and at the total hip by about 6.0%. After stopping, turnover markers rise gradually, but the rebound is slower than with oral bisphosphonates or denosumab, which is why a structured drug holiday is feasible without an immediate fracture surge.

Who Should Consider Stopping vs. Who Should Continue

Not every woman is a candidate for a drug holiday. The American Society for Bone and Mineral Research and the Endocrine Society's 2019 osteoporosis guidelines stratify women into lower-risk and higher-risk groups based on current T-score, prior fracture history, and age.

Lower-Risk Women: Drug Holiday Is Reasonable

A drug holiday after three to five annual infusions is appropriate if you meet all of these:

• Current hip T-score is higher than -2.5
• No hip or vertebral fracture occurred during treatment
• No major osteoporotic fracture in the five years before starting Reclast
• Age under 75 with no significant fall history

For this group, the National Osteoporosis Foundation and AACE joint position statement supports a holiday of roughly two to three years, with DXA repeated at that mark.

Higher-Risk Women: Continue Without a Holiday

A drug holiday is not appropriate if any of the following apply:

• Hip or femoral neck T-score at or below -2.5 at the time of stopping
• Prior fragility fracture of the hip or spine at any point
• FRAX 10-year hip fracture probability above 3% or major osteoporotic fracture probability above 20%
• Ongoing glucocorticoid use at a dose of 7.5 mg prednisone-equivalent or more per day

These women should discuss either continuing zoledronic acid or transitioning to an anabolic agent (teriparatide or romosozumab) before or instead of stopping.

Perimenopause and Early Postmenopause: A Specific Note

Bone loss accelerates sharply in the two to five years surrounding the final menstrual period. The Menopause Society's 2023 position statement emphasizes that perimenopausal and early postmenopausal women losing bone rapidly may have their fracture risk underestimated by a single T-score snapshot. If you started Reclast in perimenopause and are now postmenopausal, your risk category may have shifted, and that reassessment belongs in the stopping decision.

The Practical Discontinuation Protocol: Step by Step

Stopping Reclast is not a passive act. It requires a sequence of clinical decisions spread over several months.

Step 1: Assess Current Fracture Risk Before the Next Scheduled Infusion

At the three-year or six-year mark (depending on your initial risk), your clinician should obtain a DXA scan and recalculate your FRAX score using current BMD. FRAX is freely available from the WHO Collaborating Centre and is calibrated for women using country-specific fracture databases. Do not guess. Get the numbers.

Step 2: Measure Bone Turnover Markers at the Reassessment Visit

Serum CTX and P1NP reflect whether your skeleton's remodeling cycle has recovered toward baseline. If CTX remains deeply suppressed (below roughly 100 pg/mL) three years after your last infusion, it suggests the drug is still pharmacologically active and a holiday may naturally be in progress already. One observational analysis found that 40% of women three years after their last zoledronic acid infusion still had CTX values below the premenopausal reference range.

Step 3: Make the Holiday Decision With a Shared Framework

The WomanRx stopping framework, developed in consultation with our clinical board, groups women into three tiers at the reassessment visit:

Tier 1 (Stop and monitor): T-score above -2.0 at hip, FRAX major fracture <10%, no prior fracture. Holiday of up to three years; DXA at year two of holiday.

Tier 2 (Stop with caution): T-score -2.0 to -2.5 at hip, FRAX major fracture 10-20%, or one prior non-hip non-vertebral fracture. Holiday of one to two years maximum; DXA at 12-18 months; bone turnover markers at six and twelve months.

Tier 3 (Do not stop): T-score at or below -2.5 at hip, prior hip or vertebral fracture, or FRAX major fracture above 20%. Restart discussion with specialist, consider anabolic therapy.

Step 4: Monitor During the Holiday

While on a drug holiday from Reclast, your follow-up schedule should include:

• DXA at 18-24 months into the holiday
• Serum CTX or P1NP at 12-18 months to detect rebound resorption
• Height measurement at every visit (loss of more than 1.5 cm may signal a silent vertebral fracture)
• Lateral spine X-ray or vertebral fracture assessment (VFA) if height loss is detected

Step 5: Know When to Restart

Restart zoledronic acid (or consider an alternative agent) if any of the following occur during the drug holiday:

• Hip BMD falls by 5% or more from the value at the start of the holiday
• A new fragility fracture occurs at any site
• Bone turnover markers rise above the upper limit of the premenopausal reference range on two consecutive measurements

Why Zoledronic Acid Is Different From Other Bisphosphonates When You Stop

The discontinuation profile of zoledronic acid differs from both oral bisphosphonates and the biologic agent denosumab in ways that matter for your stopping plan.

Comparison With Oral Bisphosphonates (Alendronate, Risedronate)

Oral bisphosphonates are also retained in bone but generally produce a slower rate of BMD gain and a shorter effective tail after stopping than IV zoledronic acid. A 2017 systematic review in the Journal of Bone and Mineral Research found that after stopping alendronate, hip BMD declined by an average of 1.3% per year compared with 0.7% per year after stopping zoledronic acid over three years of follow-up, suggesting a more durable residual effect from IV therapy. The extended HORIZON study (HORIZON-E) followed women randomized to stop at three years versus continue to six years, finding that those who stopped retained clinically meaningful BMD for at least three additional years.

Comparison With Denosumab

This is where the biology diverges most sharply. Denosumab (Prolia) is a monoclonal antibody that does not bind to bone at all. It inhibits RANKL systemically, and when it is stopped, osteoclast activity rebounds rapidly, sometimes causing multiple vertebral fractures within 12 to 18 months in high-risk women. The FREEDOM Extension trial data and subsequent case series confirmed that stopping denosumab without a bridging bisphosphonate carries real fracture risk. Zoledronic acid given after stopping denosumab can blunt this rebound, which is why the sequencing of these drugs matters.

If you are currently on denosumab and your clinician is considering switching you to Reclast as a bridge, that is a different clinical situation from stopping Reclast outright, and the timing of the Reclast infusion relative to the last Prolia injection (typically within six months) is specific and protocol-driven.

Sex-Specific Physiology and Life-Stage Considerations

Reproductive-Age Women With Osteoporosis

Premenopausal women represent a small but important group who receive bisphosphonates, usually for glucocorticoid-induced osteoporosis, osteogenesis imperfecta, or other secondary causes. For this group, stopping Reclast involves additional complexity because of zoledronic acid's prolonged skeletal half-life and its known teratogenicity (see Pregnancy and Lactation below). The American College of Obstetricians and Gynecologists recommends that premenopausal women on bisphosphonates use highly effective contraception and have a documented stopping plan that accounts for pregnancy intention.

Perimenopause

In the menopause transition, estrogen withdrawal drives rapid bone resorption that can exceed two to three percent of hip BMD per year. Starting Reclast during perimenopause and planning a drug holiday needs to account for this underlying hormonal acceleration. Menopausal hormone therapy (MHT) does reduce bone loss and may be used alongside or sequentially with zoledronic acid, though combined use is generally reserved for women who have both significant vasomotor symptoms and osteoporosis, not as a strategy to extend the drug holiday. The Menopause Society's 2022 hormone therapy position statement notes that MHT is approved for prevention but not treatment of osteoporosis, which means it cannot substitute for Reclast in a woman with established fractures.

Postmenopause: The Primary Population

Most of the evidence for Reclast discontinuation comes from postmenopausal women aged 65-80, and the HORIZON-PFT population reflects this. For women in this group, the drug holiday protocol above applies directly. Women over 75 warrant individual assessment because fall risk, frailty, and comorbidities may tip the balance toward continuing therapy even with a relatively preserved T-score.

Premature Ovarian Insufficiency (POI)

Women with POI who have been on Reclast face a longer potential exposure to low estrogen than women with natural menopause timing. Bone loss after stopping Reclast in this population has not been directly studied; the evidence is extrapolated from postmenopausal trials. These women should have annual rather than biennial DXA during any drug holiday and should discuss concurrent hormone replacement with their clinician.

Pregnancy, Lactation, and Contraception: A Required Warning

Zoledronic acid is contraindicated in pregnancy. This is not a precautionary statement. Animal studies show fetal harm at clinically relevant doses, and the drug's prolonged retention in bone means that fetal exposure from maternal skeletal release is theoretically possible for years after the last infusion. The FDA classifies zoledronic acid as Pregnancy Category D (old system), meaning there is positive evidence of human fetal risk. The FDA prescribing information for Reclast states that the drug should not be used in women who are pregnant or planning pregnancy.

Contraception Requirement

Any reproductive-age woman prescribed zoledronic acid must use reliable, highly effective contraception throughout treatment. Because the drug persists in bone and may be released during skeletal remodeling in pregnancy, the contraception requirement logically extends beyond the last infusion, though the precise duration is not defined in labeling. Current expert consensus recommends continuing contraception for at least 12 months after the final dose, with individualized extension based on fracture risk (since restarting therapy after a planned pregnancy would be the clinical path).

Lactation

Zoledronic acid has not been studied in human breast milk. Given its high bone affinity and limited systemic circulation after initial skeletal uptake, the actual transfer to breast milk may be small. The FDA label advises against use during breastfeeding. Clinicians generally recommend holding zoledronic acid until after lactation is complete and then reassessing bone density before deciding whether to restart.

Postpartum Osteoporosis

A separate clinical scenario arises when a woman develops pregnancy-associated osteoporosis (PAO) or postpartum osteoporosis after breastfeeding. In these cases, zoledronic acid has been used off-label after lactation ends. The evidence is case-series level only, and decisions should be made at a specialized center. A 2020 review in Osteoporosis International summarized 54 published cases of pregnancy-associated osteoporosis managed with bisphosphonates, finding partial BMD recovery in most, but noting that no randomized data exist.

Conditions That Intersect With Zoledronic Acid Use in Women

Glucocorticoid-Induced Osteoporosis

Women with inflammatory conditions such as rheumatoid arthritis, lupus, or asthma who use long-term corticosteroids face higher fracture risk at any given BMD. ACR's 2022 guideline for glucocorticoid-induced osteoporosis recommends bisphosphonate therapy for women over 40 on prednisone 2.5 mg or more daily for three months or longer. Stopping Reclast in this population is more conservative: a drug holiday is generally not recommended while the glucocorticoid is ongoing.

PCOS and Bone Health

Women with polycystic ovary syndrome (PCOS) have a complex bone metabolism profile. Chronic anovulation reduces estrogen exposure and may impair bone accrual, but hyperandrogenism may partially offset this. Zoledronic acid is not a first-line treatment for PCOS-related bone concerns, but women with PCOS who develop premature osteoporosis may receive it. Specific stopping guidance for this subgroup has not been defined in trials; decisions borrow from the broader premenopausal osteoporosis framework.

Breast Cancer Survivors

Women on aromatase inhibitors (AIs) for hormone receptor-positive breast cancer experience accelerated bone loss of one to two percent per year at the spine. The ABCSG-12 and ZO-FAST trials established that zoledronic acid given every six months during AI therapy prevents this bone loss and may reduce disease recurrence. For breast cancer survivors, stopping zoledronic acid follows a different schedule (every six months rather than annually, and the drug holiday question is handled by the oncology team, not the primary care or gynecology clinician). This article focuses on the standard osteoporosis indication, but if you are a breast cancer survivor on AI therapy and Reclast, the decision to stop belongs in an oncology-gynecology shared visit.

Rare but Serious Risks to Discuss Before Stopping or Continuing

Osteonecrosis of the Jaw (ONJ)

The risk of medication-related ONJ (MRONJ) with Reclast at the osteoporosis dose is very low, estimated at approximately 1 in 10,000 to 1 in 100,000 patient-treatment years based on pharmacovigilance data. Risk increases with duration of therapy and any planned invasive dental work. Before any major dental procedure (extraction, implant, bone graft), your clinician may pause the next infusion for three to six months if the jaw bone has adequate healing reserves. Stopping Reclast for a drug holiday does not eliminate ONJ risk entirely, given the drug's skeletal persistence.

Atypical Femoral Fracture (AFF)

Atypical femoral fractures, which occur in the subtrochanteric or diaphyseal femur, are strongly associated with long-term bisphosphonate use. A large cohort study published in JAMA Internal Medicine found the rate of AFF rose with treatment duration: approximately 1.8 per 100,000 person-years at two years of use, rising to 113 per 100,000 person-years at eight or more years. This risk gradient is one clinical reason the drug holiday exists. Report any new thigh or groin pain to your clinician immediately, whether you are on the drug or on a holiday.

Who This Is Right For and Who Should Take a Different Path

Women for Whom Stopping Reclast Makes Clinical Sense

• Postmenopausal women who have completed three annual infusions with a favorable response (BMD rise, no new fractures)
• Women whose T-score has improved to above -2.0 at the femoral neck during treatment
• Women age 65-75 without major fall risk, frailty, or secondary causes of bone loss
• Women who experienced bothersome but manageable acute-phase reactions (flu-like symptoms after infusion) and prefer a break

Women Who Should Not Stop Without Expert Guidance

• Women with a history of hip fracture or morphometric vertebral fracture
• Women on long-term glucocorticoids at any dose
• Women transitioning off denosumab who received Reclast as a bridge (stopping Reclast in this sequence carries its own risk)
• Women with very low BMD (T-score at or below -3.0 at any site) at the time of stopping consideration
• Women with secondary osteoporosis from malabsorption, celiac disease, or primary hyperparathyroidism whose underlying condition is not controlled

Bone Turnover Markers: Your Window Into What the Drug Is Still Doing

Serum CTX (fasting, morning sample) and P1NP are the two markers used clinically to assess whether zoledronic acid's suppressive effect is waning. The International Osteoporosis Foundation's position on bone turnover markers recommends using them to monitor antiresorptive therapy response and to detect rebound after stopping.

During a drug holiday, a CTX value above approximately 300-400 pg/mL (laboratory-specific reference ranges apply) suggests that resorption is no longer meaningfully suppressed and the drug's active reservoir in bone is depleting. At that point, restarting an infusion or transitioning to another agent depends on your current DXA result and fracture history. Do not use bone turnover markers alone to make restart decisions. They inform the picture; they do not close the case.